Highest-materiality recent filing
Rani Therapeutics shareholders elect all 7 directors, ratify auditor at 2026 annual meeting
All director nominees elected with >57M votes each; Jean-Luc Butel had highest withhold (4,997,042).
Rani Therapeutics raises $20M via common stock and pre-funded warrant offering
Issues 12.48M shares at $1.07/share and pre-funded warrants for 6.21M shares at $1.0699.
Rani Therapeutics Q1 net loss narrows to $8M; Nasdaq bid price non-compliance; CFO to depart
Q1 net loss $8.0M, narrowed from $12.7M YoY; cash $43.4M expected to fund operations into Q4 2027.
Collaboration with Chugai for up to $1.085B to develop oral therapy using RaniPill; Chugai may expand to 5 additional targets.
Rani Therapeutics terminates TRA, adopts governance changes reducing Class B voting to 1 vote
Terminated Tax Receivable Agreement with InCube Labs; no payments or early termination fees required.
Entered collaboration with Chugai for oral therapy using RaniPill platform; potential total value up to $1.085B including options for up to five additional targets.
Rani Therapeutics closes private placement of 42.6M shares and warrants; board changes
Closed private placement of 42,633,337 shares of Class A common stock, warrants to purchase 125,000,004 shares, and pre-funded warrants for 82,366,667 shares.
Rani raises $60.3M, partners with Chugai on hemophilia drug via RaniPill
Private placement: ~$60.3M gross from 42.6M shares and warrants at $0.48/share (institutional) and $0.605 (affiliate).
Rani Therapeutics Q2 net loss $11.2M, cash at $10.2M; collaboration with Chugai announced
Net loss of $11.2M for Q2 2025 vs $13.4M in Q2 2024; includes $3.3M stock-based compensation.
Rani Therapeutics raises $3.0M via stock and warrant offering; suspends ATM facility
Entered securities purchase agreement to issue 4.354M shares and 3.146M pre-funded warrants at $0.40/share.
Rani Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure ends Dec 17
Received Nasdaq notice on June 20, 2025 for non-compliance with $1.00 minimum bid price (30 consecutive business days below $1.00).
Rani Therapeutics annual meeting elects 7 directors, ratifies auditor
All seven director nominees (Talat Imran, Mir Imran, Ausiello, Butel, Farquharson, Nanavaty, Rometty) elected; ~229.4M for each.
Rani Therapeutics induces warrant exercise by Armistice, receives ~$4.3M
Gross proceeds of ~$4.3M from cash exercise of Series B & C warrants at reduced exercise price of $0.65/sh.
Rani Therapeutics Q1 net loss $12.7M, cash $15.9M; RT-114 Phase 1 mid-2025
Net loss was $12.7M for Q1 2025 ($14.8M in Q1 2024); cash, equivalents and marketable securities fell to $15.9M from $27.6M at year-end.
Rani Therapeutics receives Nasdaq deficiency notice for MVLS below $50M
Nasdaq notified Rani on May 1, 2025 that its Market Value of Listed Securities was below $50M for 30 consecutive business days.
Director Laureen DeBuono retires from Rani Therapeutics board; committees reconstituted
Laureen DeBuono resigned from Board effective April 24, 2025; no disagreement with company.
Rani Therapeutics auditor Marcum resigns; FY2024 report had going concern note
Marcum resigned as independent auditor on April 7, 2025; Audit Committee accepted resignation.
FY2024 net loss of $56.6M vs $67.9M in 2023; cash and marketable securities $27.6M, expected to fund operations into Q3 2025.
Rani Therapeutics Q3 net loss $12.7M; cash $30.4M extended into Q3 2025
Net loss of $12.7M for Q3 2024, compared to $18.3M in Q3 2023; includes $4.1M stock-based comp.
Rani Therapeutics to raise ~$10M via stock/warrant offering; cancels prior warrants
Issuing 3M shares + pre-funded warrants for 333K shares + Series C warrants for 3.33M shares at $3.00 combined price.
Rani Therapeutics dismisses EY as auditor, appoints Marcum; EY's 2023 report had going concern doubt
EY dismissed as independent auditor on Sep 10, 2024; Marcum LLP appointed immediately.
Cash, equivalents and marketable securities totaled $30.9M as of June 30, 2024, down from $48.5M at Dec. 31, 2023.
Rani Therapeutics raises $10M via registered direct offering with warrants
Gross proceeds ~$10M from sale of 2.8M shares, 446,753 pre-funded warrants, and warrants for 6.5M shares.
Rani Therapeutics decides not to pursue equity financing after investor talks
Engaged in discussions with investors for a potential equity financing but elected not to proceed.
Parties will share development costs and operating profits/losses equally; Rani leads US, Canada, Europe, Australia development after Phase 2.
Rani Therapeutics announces annual meeting results; all director nominees elected
Annual meeting held May 29, 2024; all eight director nominees elected with overwhelming support.
Rani Therapeutics Q1 net loss $14.8M; cash $39.6M; RT-111 Phase 1 positive
Cash, cash equivalents and marketable securities: $39.6M at March 31, 2024 (down from $48.5M year-end 2023).
Rani Therapeutics FY2023 net loss $67.9M; cash $48.5M; positive Phase 1 for RT-111 oral antibody
Net loss for FY2023 was $67.9M ($63.3M in 2022); cash and equivalents $48.5M (down from $98.5M at year-end 2022).
On May 12, 2026, Svai Sanford, the Company’s Chief Financial Officer, advised the Company that he will resign from his position following the appointment of his successor.
On April 24, 2025, Laureen DeBuono notified the Board of Directors (“Board”) of Rani Therapeutics Holdings, Inc. (the “Company”) that she has decided to retire from the Board effective immediately.
Max materiality 0.90 · Median 0.65 · Most common event other_material